They accuse their neurologists and the French drug manufacturer Sanofi, which produces Depakine, of failing to warn them about the risks to the fetus, according to reports published on Le Matin Dimanche and SonntagsZeitung.
Depakine is still widely used today to treat epilepsy and migraines. Scientists have established that the sodium valproate contained in the drug creates psychomotor, cognitive and mental development disorders in 30 to 40% of cases.
The Swiss expecting mothers were not made aware of these dangers. A warning from agency for therapeutic products, Swissmedic, came to late.
In Switzerland, 39 children have been born with brain damage in connection to Depakine use, according to a report commissioned by the government.
Thierry Buclin, a professor of clinical pharmacology at the University Hospital of Lausanne suspects the actual figure is much higher.
The professors, who was quoted in the media reports, says the government study is incomplete. It does not consider the transgenerational effect of Depakin which has been brought to light by recent scientific studies.
The controversial drug has been authorised in Switzerland since the 1970s. Such side effects were not mentioned in the package leaflet until 2015.
In neighbouring France, as many as 6,500 children have been negatively affected by Depakine. The victims launched a collective action against Sanofi at the end of 2016 to obtain compensation.
The first complaint was made in Switzerland in 2017 by a woman who had been using the drug since adolescence and even had her dosage raised by her neurologist during one of her pregnancies. She gave birth to two children who suffer from severe cognitive disorders and autism.
Popular Stories
More
Swiss Politics
In Switzerland, New Year brings ‘burqa ban’ and pension hikes
Should Switzerland take measures to support its struggling industries?
Industrial policies are back in fashion, not only in the United States but also in the EU. Should Switzerland, where various industries are struggling, draw inspiration from such policies?
Swiss plan 1,600 extra trains for Eurovision, Women’s EURO 2025 and other events
This content was published on
Swiss Federal Railways is planning to operate 1,600 additional trains to transport passengers to special events in 2025, such as the UEFA Women's EURO 2025 and the Eurovision Song Contest.
Swiss study: higher prices for cheese with protected geographical indication
This content was published on
Indications of geographical origin play a central role in the cheese trade, a study by the Agroscope research centre shows.
Swiss campaigners launch another ‘responsible business initiative’
This content was published on
A coalition has launched a new "responsible business initiative", urging the government to ensure that Swiss-based multinationals and their subsidiaries abroad respect human rights and protect the environment.
Swiss court suspends Geneva plan to ban single-use plastics
This content was published on
A Geneva court has suspended a ban on the sale of single-use plastics in the city, which was due to be introduced on January 1. This follows an appeal by Swiss retailers to the Federal Court.
Swiss cable car firms and hotels report positive winter so far
This content was published on
The Swiss cable car association and Switzerland Tourism have reported higher visitor numbers at winter resorts over the Christmas and New Year period compared to 2023/24.
UBS expects Swiss National Bank to record CHF80bn profit in 2024
This content was published on
The Swiss National Bank (SNB) is expected to make a net profit of CHF80 billion ($88.4 billion) in 2024, according to UBS.
This content was published on
Consumer prices fell last year in Switzerland, new figures show. Higher rents and electricity prices were partially offset by lower prices for gas and prescription drugs.
This content was published on
New data from the Federal Office of Public Health (FOPH) shows that flu cases doubled in Switzerland between mid and late December.
Swiss bank Julius Bär sells its Brazilian operation
This content was published on
Swiss private bank Julius Bär has signed an agreement to sell its operation in Brazil for 615 million reais, or CHF91 million ($100.7 million).
Historian claims Swiss banks may hold further Second World War secrets
This content was published on
Bank archives could still hold secrets about Swiss actions during the Second World War and should be re-examined, especially those of UBS, says Marc Perrenoud, a historian who worked on the Bergier Commission.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis and Microsoft to develop drugs using AI
This content was published on
Novartis and Microsoft have signed a five-year partnership aimed at transforming the Basel-based pharma’s business using AI.
Gaps found in opioid prescription oversight in Switzerland
This content was published on
In the wake of the opioid crisis in the US, some medical professionals in Switzerland are warning about over-prescription of oxycodone drugs.
Swiss pharmaceutical firm lets dogs die cruel death
This content was published on
Dogs are being left to die in agony in Germany after lab testing for the Swiss pharma company Inthera Bioscience, says a report.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.